TD Cowen analyst Yaron Werber raised the firm’s price target on BeiGene to $254 from $236 and keeps a Buy rating on the shares. The firm said Brukinsa beat was solid, and the CLL launch continues in the US/EU pacing it to be the leading BTKi.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE:
- New Risks Emerge for BeiGene: Investors Alerted to Material Updates in Financial Disclosures
- BeiGene reports Q1 EPS ($2.41), consensus ($2.54)
- BeiGene price target raised to $236 from $235 at TD Cowen
- BeiGene receives European Commission approval for tislelizumab
- Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
